A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study.

Introduction Multiple monoclonal antibody (mAb) treatments have been developed to combat the growing number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains. These treatments have been shown to be effective in reducing the risk of hospitalization and death from SARS-CoV-2 infection with a low risk of adverse effects; however, more data is required to evaluate the comparative efficacy of mAbs. The primary objective of this study is to describe the hospitalization rate, length of stay (LOS), and mortality rate in SARS-CoV-2 patients treated with four different mAb treatments, including bamlanivimab plus etesevimab, casirivimab plus imdevimab, sotrovimab, and bebtelovimab. Methods A retrospective chart review and prospective phone surveys of SARS-CoV-2 patients treated with mAbs in a 400-bed tertiary, suburban medical center were conducted between June 2020 and April 2022. Eligibility criteria for mAbs included non-hospitalized patients over the age of 18 with less than 10 days of SARS-CoV-2 symptoms and no oxygen requirement on emergency department (ED) admission. Data were collected from the retrospective chart review and subjective patient surveys. A chi-squared test was used. Significance was assessed at p < 0.05. Results The study population included 3249 patients, with 1537 males and 1712 females and an average age of 62.48 ± 17.54 years. Five hundred forty-two patients received bamlanivimab plus etesevimab; 849 received bebtelovimab; 1577 received casirivimab plus imdevimab; and 281 received sotrovimab. The overall hospitalization rate was 1.0%, and the mortality rate was 0.2% following mAb treatment. The hospitalization rate was greatest among patients administered Sotrovimab (2.1%) and least among patients administered Bebtelovimab (0.1%) (p = 0.010). 2.4% of patients who were discharged from the ED after receiving one of the four mAbs returned within 30 days with SARS-CoV-2 symptoms. The average length of stay was 4.75 ± 4.56 days, with no significant differences between the mAbs. The provider-reported adverse event rate was 2.2%, with significant differences in adverse event rates between mAbs. Bamlanivimab-etesevimab was associated with the highest adverse event rate (4.6%), and sotrovimab was associated with the lowest adverse event rate (1.4%) (p < 0.001). Conclusion This study shows a low hospitalization and mortality rate following mAb infusion in patients with mild and moderate COVID-19. However, there were significant differences in hospitalization and mortality among patients receiving each of the four mAb treatments. There was a high degree of patient-reported symptom improvement, and adverse reactions were reported in only 2.2% of patients with no severe reactions. Multiple monoclonal antibody treatments are not effective as monotherapy; however, this study shows the potential benefits of including a mAb infusion as part of a SARS-CoV-2 treatment plan.

Evaluation of a Multicomponent Care Transitions Program for High-Risk Hospitalized Older Adults.

OBJECTIVES: To test the effectiveness of a multicomponent care transition intervention targeted at hospitalized patients, aged 75 years and older, at high risk for hospital readmissions, return emergency department (ED) visits, and related complications. DESIGN: Implementation as a quality improvement program with propensity-matched preintervention and concurrent comparison groups over a 12-month period. SETTING: A 400-bed community teaching hospital. PARTICIPANTS: Patients, aged 75 years and older, admitted to non-intensive care unit beds who met specific high-risk criteria. The intervention group included 202 patients, and the concurrent and preintervention comparison groups included 4142 and 4592 patients, respectively. MEASUREMENTS: Primary outcomes were 30-day hospital readmissions and returns to the ED; 7-day readmissions and ED visits were secondary measures. RESULTS: Among the 202 patients enrolled in the "Safe Transitions for At-Risk Patients" ("STAR") program, 37 (18.3%) were readmitted within 30 days, in contrast to 14.3% and 14.6% in the concurrent and preintervention comparison groups, respectively. Rates for 30-day return ED visits that did not result in hospitalization were 10.9% in the intervention group, and 7.2% and 7.9% in the comparison groups. STAR patients had greater 30-day ED use than patients in the preintervention comparison group (5.0 percentage points; 95% confidence interval = 0.8-9.3 percentage points; P = .020). Implementation challenges included suboptimal involvement of the participating hospital and post-acute care organizations and a relatively high proportion of patients who did not receive the intervention as planned, despite agreeing to participate before leaving the hospital. CONCLUSION: A multicomponent care transitions intervention targeting high-risk patients, aged 75 years and older, admitted to a community teaching hospital was not effective in reducing 30- or 7-day readmissions or return ED visits. Our implementation experience offers many lessons for future programs for similar high-risk geriatric populations. J Am Geriatr Soc 67:2634-2642, 2019.

Usefulness of carotid ultrasound to improve the ability of stress testing to predict coronary artery disease.

Carotid ultrasound is a useful tool to detect plaque and measure carotid intimal-medial thickness (CIMT), which help identify asymptomatic patients at risk of cardiovascular events. However, the role of carotid ultrasound in stratifying risk in symptomatic patients has not been studied. We prospectively examined the hypothesis that in symptomatic patients undergoing exercise (or pharmacologic) stress testing (EST), CIMT and carotid plaque will improve the ability to identify patients with > or =50% coronary diameter stenosis. Mean and maximal CIMTs were measured in 50 symptomatic patients without known coronary artery disease (CAD) who were scheduled to undergo diagnostic angiography after EST with imaging. Pretest probability of CAD was calculated for each patient based on age, gender, and nature of symptoms. Fifty percent of patients were men, 32% were diabetic, 70% had hypertension, and 58% had dyslipidemia. CAD > or =50% was associated with CIMT in the >75th percentile (74% vs 44%, p = 0.047) and with presence of carotid plaque (96% vs 59%, p = 0.003). Of patients with an equivocal/negative EST result (n = 38), those with carotid plaque had a 46% (13 of 28) prevalence of significant CAD; in the smaller subset of patients without carotid plaque (n = 10), none had luminal stenosis > or =50% (p = 0.007). Pretest probability of CAD, presence of carotid plaque, moderately/severely abnormal EST result, and hypertension were independent predictors of significant CAD. In conclusion, carotid ultrasound appears to offer incremental value to EST in predicting presence or absence of > or =50% coronary diameter stenosis in symptomatic patients with equivocal/negative EST result.